Predilife presents its Breast Check-Up, with the MammoRisk® test
Since 2019, Predilife has been marketing MammoRisk®, the first breast cancer risk prediction solution in France, providing women with a clear report for personalised screening.
The MammoRisk® test integrates the latest scientific knowledge in terms of risk factors (clinical data, imaging and medical biology) in order to provide each woman with unique and adapted monitoring.
Today, all women aged 40 and over can request a Breast Check-Up from their doctor and obtain a breast cancer risk assessment.
More information available at: www.cancerdusein.predilife.com
MammoRisk® is a Class I medical device manufactured by Predilife. It is a regulated health product which carries the CE mark under these regulations.
Read the user manual carefully before use. MammoRisk® is not a diagnostic test. MammoRisk® is a breast cancer risk assessment test.